Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | LMNA | P02545 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480273 | 1.00 | MAPT (0.70) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5483065 | 0.90 | MAPT (0.64) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5483943 | 0.89 | MAPT (0.57) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5483941 | 0.89 | MAPT (0.57) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5487131 | 0.83 | LMNA (0.52) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5487127 | 0.83 | LMNA (0.52) | MAPTLMNASMN1; SMN2GAAHTT | |
| SCHEMBL5486927 | 0.81 | LMNA (0.54) | MAPTLMNASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL5486932 | 0.81 | LMNA (0.54) | MAPTLMNASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL4563772 | 0.77 | CYP1A2 (0.69) | MAPTLMNASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL781659 | 0.76 | CYP1A2 (0.87) | MAPTLMNASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | MAPT 1549/4885LMNA 3693/4885SMN1; SMN2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.